Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLARIS trial of WIN378 in moderate to severe asthma
2025-521391-58-00Phase 2Authorised
- Sponsor
- Windward Bio
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing WIN378 with Matching placebo for WIN378 (2 arms). Primary endpoints: Safety and tolerability and Pharmacokinetics and immunogenicity. Planned start Nov 2025; status: authorised.
02
Drugs
WIN378
03
Conditions
asthma
Beyond the preview
Go deeper on 2025-521391-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521391-58-00.